Loading company…
Vaderis Therapeutics develops targeted therapies for rare vascular diseases.
Founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, Vaderis Therapeutics develops treatments for rare vascular diseases. The clinical-stage biopharmaceutical company is based in Basel, Switzerland. In August 2026, it raised USD 152 million in Series B funding co-led by Goldman Sachs Asset Management and TCG Crossover Management, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital Management, Droia Ventures, and Medicxi.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in